Overview Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential Blepharospasm Status: Completed Trial end date: 0000-00-00 Target enrollment: Participant gender: Summary The purpose of this study is to compare the effectiveness of 3 doses of Dysport® with placebo by assessing functional disability in blepharospasm. Phase: Phase 2 Details Lead Sponsor: IpsenTreatments: abobotulinumtoxinABotulinum ToxinsBotulinum Toxins, Type AincobotulinumtoxinAonabotulinumtoxinA